Kornimate/medical-research-clean huggingface dataset:
thoracic paravertebral block, erector spinae plane block, and in combined paravertebral-erector spinae block

Conditions: Pain, Postoperative; Thoracic Surgery, Video-Assisted; Thoracic Paravertebral Block; Erector Spinae Plane Block

Summary: video-assisted thoracic surgery (vats) has become a common procedure in thoracic surgery. severe postoperative pain may be encountered in patients undergoing vats. analgesic methods such as thoracic paravertebral block (tpvb), intercostal block and erector spina plane block (espb) are widely used for vats. among these methods, ultrasound (us) guided tpvb is the most preferred method. generally, comparisons are made between espb and tpvb in studies and the analgesic effect is evaluated. however, no research could be found in the literature combining espb and tpvb. the mechanisms of regional analgesia techniques used after thoracic surgery operations are also different from each other. therefore, it may be possible to obtain a more effective analgesic effect in patients by combining the mechanism of action of tpvb and espb, as in the multimodal analgesia method. this study seeks to evaluate the effect of tpvb, espb and combined tpvb-espb pain after vats.


Eligibility criteria:
inclusion criteria: * 18 to 80 years old * asa physical status i-ii-iii * bmi 18 to 30 kg/m2 * elective video assisted thoracoscopic surgery exclusion criteria: * patient refusing the procedure * emergency surgery * chronic opioid or analgesic use

Keywords: erector spinae block, thoracic paravertebral block, vats
a study to evaluate efficacy and safety of deucravacitinib in participants with alopecia areata

Conditions: Alopecia Areata

Summary: the purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.


Eligibility criteria:
inclusion criteria: * documented clinical diagnosis of alopecia areata (aa) for at least 6 months. * current episode of scalp hair loss (at screening) must meet the following criteria: duration at least 6 months; duration of current hair loss episode of aa affecting ≥ 50% of the scalp not exceeding 8 years; scalp hair loss has been stable (no significant spontaneous regrowth \[\> 10%\] over the last 6 months) * salt score ≥ 50 at screening and day 1. participant with complete scalp hair loss (salt score of 100) with or without body hair involvement can be included. exclusion criteria: * participant with diffuse-type aa or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc. * other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of salt score. * extensive tattooing of the scalp that, in the opinion of the investigator, may interfere with the accurate assessment of salt score. other protocol-defined inclusion/exclusion criteria apply.

Keywords: deucravacitinib im011134 bms-986165
evaluation of early mucosal healing during clinical remission in pediatric ulcerative colitis

Conditions: Ulcerative Colitis

Summary: establishing that mucosal healing (mh) has occurred after therapy is an important treatment goal, and the gold standard is endoscopic evaluation. in uc it is unclear if clinical parameters are adequate. the pediatric ulcerative colitis activity index (pucai) has demonstrated good correlations for clinical remission and disease severity, but its role for establishing mucosal healing after therapy has not been validated . the ability to predict mucosal healing may be different for patients in long term remission compared to assessment after obtaining clinical remission. no previous study has prospectively validated the use of pucai as a proxy for mh specifically during clinical remission after therapy.

all pediatric patients ≤ 19 years old and at the wolfson medical center pediatric ibd center who enter clinical remission are routinely assessed by colposcopy or sigmoidoscopy assess. this is an analysis of prospectively collected data regarding pucai and endoscopic mayo score at the time of assessment of mucosal healing by endoscopy. patients could be included if they have establish ulcerative colitis, while they are on remission for at least 3 months after treatment of flare. for this study, complete clinical remission was absence of abdominal pain, and no diarrhea or bleeding (pucai\<10). sigmoidoscopy will be performed between 12-24 weeks after remission was documented.

Eligibility criteria:
inclusion criteria: 1. ulcerative colitis patient 2. clinical remission (pucai\<10) for at least 3 months. 3. sigmoidoscopy for assessment mucusa healing after therapy performed between 12-24 weeks after remission was documented - -
clinical study of liraglutide in improving cardiac function for patients with ischemic cardiomyopathy

Conditions: Ischemic Cardiomyopathy

Summary: it has been known that liraglutide reduces infarct size, improved left ventricular function, reduce myocardial stunning, and play a protective role in myocardial ischemia-reperfusion injury for patients with acute myocardial infarction. but it is not sure whether liraglutide can benefit patients with ischemic cardiomyopathy. this study aim to explore the effect of liraglutide in improving cardiac function for patients with ischemic cardiomyopathy.

investigators will enroll 400 patients with ischemic cardiomyopathy who were admitted to the chinese pla general hospital. all patients enrolled in this study will collect detailed baseline clinical data, including blood, enzymes (troponin, creatine kinase), blood sugar, serum creatinine, blood lipid levels (ldl lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, total cholesterol), brain natriuretic peptide (bnp), inflammatory markers (high sensitivity c- reactive protein, interleukin-6), endothelin (et-1), pancreas glucagon-like peptide -1 (glp-1) and superoxide dismutase (sod). the investigators randomly assign eligible patients in a 1:1 ratio to either liraglutide intervention group (n = 200) or control group (n = 200), liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and liraglutide (novo nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day), control group will accept ischemic cardiomyopathy conventional drugs and a placebo. primary end point of the study is main adverse cardiovascular events including recurrent myocardial infarction, recurrent angina, revascularization, all-cause death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure again. secondary end point of the study was 1) new york heart association functional class, 2) left ventricular ejection fraction, 3) 6-minute walk test, 4) kccq clinical total score, 5) changes in blood glucose levels during follow-up, blood lipid levels and body weight

Eligibility criteria:
inclusion criteria: * patients with ischemic cardiomyopathy: the clinical manifestations of heart failure (nyha class ii-iv grade), evidence of cardiac dysfunction (lvef ≤40%, and lvedd ≥55mm) and previous coronary angiography showed one or more severe coronary artery stenosis. exclusion criteria: * valvular heart disease * dilated cardiomyopathy * patients requiring emergency pci * patients with cardiogenic shock; * there have been recent acute myocardial infarction in one month; * there have been recent acute stroke in one month; * estimated glomerular filtration over rate egfr \<30ml / min / 1.73m2 (according to mdrd formula); * malignant tumor * severe liver failure * respiratory failure
deb-tace with visualable microspheres versus pva microspheres for hcc

Conditions: Hepatocellular Carcinoma

Summary: this study will evaluate the safety and efficacy of deb-tace with visualable embolization microspheres versus pva microspheres for hepatocellular carcinoma.

this study is a prospective, multicenter, randomized controlled, non-inferior trial to evaluate the safety and efficacy of deb-tace with visualable microspheres or pva microspheres for hepatocellular carcinoma.

Eligibility criteria:
inclusion criteria: * cnlc ia-iiia hcc patients who require transarterial chemoembolization (tace) and are not suitable for or refuse surgical resection, liver transplantation, or ablation liver function classification of child-pugh a or b * ecog ps score of 0-2 * with measurable lesions that had not been embolized (if there are more than 3 lesions, select the three largest lesions as target lesions, and the maximum diameter of target lesion is ≤10cm) * agree to participate in this trial and voluntarily sign the informed consent form exclusion criteria: * target lesions were embolized, or will require concomitant ablation or radiotherapy after tace treatment(s) * with diffuse liver tumor or extrahepatic metastasis, expected survival \<6 months with sepsis or multiple organ dysfunction * severe liver dysfunction (child-pugh c) , or severerenal dysfunction (blood creatinine \>2 mg/dl) * significant reductions in white blood cells or platelets (white blood cells \ 3 seconds above the upper limit of normal) * with severe infection (\>5 times the upper limit of normal white blood cells) the main portal vein was completely embolized by tumor thrombus without collateral blood supply * with risk of ectopic embolization (uncorrected arteriovenous fistula or portal venous fistula) in the target lesion supplying arteries * angiography shows vascular anatomy obstruction or vasospasm that will affect the catheter placemenr embolic agent injection * known allergy to iodine-containing contrast agents, polyvinyl alcohol materials or anthracycline t ochemotherapy drugs * pregnant or lactating women * patients who are participating in other trial(s) * unsuitable for participation in this trial deemed by the researchers

Keywords: hepatocellular carcinoma tace microspheres
shanghai mild cognitive impairment cohort study

Conditions: Mild Cognitive Impairment

Summary: this study was planned 1) to identify individuals with mild cognitive impairment (mci) who convert to alzheimer's disease (ad), and 2) to explore factors associated with the conversion.


Eligibility criteria:
inclusion criteria: 1. cognitive concern reflecting a change in cognition reported by the patient or informant or clinician 2. mini-mental state examination (mmse) scores between 18-30 (inclusive) 3. clinical dementia rating (cdr) =0.5; memory box score must be at least 0.5 4. objective memory loss\* as evidenced by auditory verbal learning test (avlt-hs) 5. essentially preserved activities of daily living based on alzheimer's disease cooperative study - activities of daily living (adcs-adl) 6. not-demented, as defined by '"all-cause dementia" (see 3.4. all-cause dementia) 7. willing to and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up 8. written informed consent for the participation of this study including repeated neuropsychological tests and mri scans

Keywords: mild cognitive impairment alzheimer's disease
epidemiology of inflammatory bowel disease in the songpa-kangdong district, seoul, korea.

Conditions: Crohn's Disease; Ulcerative Colitis; Epidemiology; Korea

Summary: the purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of crohn's disease and ulcerative colitis over time in a district of seoul, korea.

inflammatory bowel disease (ibd), which is comprised of crohn's disease (cd) and ulcerative colitis (uc) is a chronic inflammatory disease of gut with uncertain etiopathogenesis. according to our previous study (yang, et al. inflamm bowel dis 2008; 14: 542-549), the incidence and prevalence of ibd in korea are still low compared with those in western countries, but are rapidly increasing. however, the long-term trends of epidemiology of cd and uc together with their characteristics and prognosis in korea are uncertain yet. the investigators therefore aim to elucidate the incidence and prevalence of cd and uc over a 30-year period, from 1986 to 2017, in the songpa-kangdong district of seoul, korea. in addition, the investigators also aim to reveal the clinical features at the time of diagnosis of ibd, long-term evolution of disease and prognosis.

Eligibility criteria:
inclusion criteria: * definite cases of cd and uc patients are diagnosed with cd if they meet at least 2 of the following criteria: 1. clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding 2. endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease 3. radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration 4. macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy 5. pathologic findings of transmural inflammation and/or epithelioid granulomas only patients who meet these criteria for at least 2 months are included. patients are diagnosed with uc only if all 3 of the following criteria are present 1. a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks 2. a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa 3. characteristic histopathological signs of inflammation on biopsy exclusion criteria: * ibd unclassified * ethnic groups other than korean

Keywords: crohn's disease ulcerative colitis epidemiology korea
inspiratory muscle training on diaphragm thickness, inspiratory muscle pressure and physical function

Conditions: Healthy

Summary: fatigue of the respiratory muscles is one of the limitations of exercise at high intensity, although the mechanisms that explain it are not yet clear. this fatigue would cause a decrease in physical performance and could limit the functional capacity of the subject. in this sense, it has been shown that specific training of respiratory muscles, especially inspiratory muscles, improves their strength and resistance both in healthy people and in people with pathologies; managing to improve the quality of life and both physical and sports performance. this study, which follows the quantitative method and proposes an analytical, experimental, longitudinal and prospective design (with the aim of conducting a randomized clinical trial), proposes an intervention based on performing a specific training of inspiratory muscles for 8 weeks, taking 30 maximum inspirations at 60% of the pim (maximum inspiratory pressure), 2 times a day for 5 days a week; with the aim of assessing the effects on inspiratory function, cardiorespiratory fitness when performing a stress test (harvard step test) and diaphragm thickness measured by ultrasound. 40 healthy subjects between 18 and 25 years old will be recruited and divided into two groups: an experimental group (n = 20) and a control group (n = 20).


Eligibility criteria:
inclusion criteria: * healthy university students exclusion criteria: * suffering or having suffered aortic aneurysm; pneumothorax; rib wall or pulmonary fistulas; recent trauma or surgery to the upper airway or thoracoabdominal; recent myocardial infarction or angina; retinal detachment, glaucoma, or recent eye surgery; increased intracranial pressure (tonsillar wedge, meningocele, hydrocephalus); abdominal hernias and acute middle ear problems.
french national registry: art registry (observational study)

Conditions: RheumatoId Arthritis

Summary: rheumatoid arthritis (ra) is a complex and multifactorial autoimmune disease. the biological treatments that are currently available for the treatment of ra are the tnf-alpha inhibitors. tumor necrosis factor (tnf) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. the anti-tnfs were the first to enter the market, and they revolutionised the prognoses of patients with ra. they remain the most common first-line biotherapy and are the most used at this time. the french society of rheumatologists intends to coordinate a prospective national registry study for this follow-up. this registry will include 1500 ra patients from the start of treatment with anti-tnf-α and then followed for 5 years, regardless of the therapeutic modifications occurring thereafter. this registry is an observational, multicentre, longitudinal, prospective registry study the objectives of this registry is to contribute 1) to evaluate the therapeutic management of patients; and 2) to improve this therapeutic management.

design: observational, multicentre, longitudinal, prospective registry primary objective: to evaluate the real life efficacy and safety of anti-tnf inhibitors in patients with ra using a prospective national registry. target population: patients initiating anti-tnf therapy for ra (including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market) number of patients and centres : more than 80 centers in france (hospital-based, public and private practice) recruitment period: 3 years follow-up: 5 years

Eligibility criteria:
inclusion criteria: * adult patients with ra, * patient in whom the specialist physician decides to start treatment with an anti-tnf drug, regardless of the treatment line and regardless of the anti-tnf, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market * clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription exclusion criteria: * patient already treated by the same anti-tnf in the past (same drug).

Keywords: rheumatoid arthritis (ra) tnf-alpha inhibitors
biomarker study in samples from patients with malignant rhabdoid tumor of the kidney or atypical teratoid rhabdoid tumor

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor; Rhabdoid Tumor of the Kidney

Summary: this research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in dna and identify biomarkers related to cancer.

primary objectives: i. to determine if there are molecular differences between rhabdoid tumor of the kidney (rtk) and the atypical teratoid rhabdoid tumor (atrt). outline: archived tumor tissue samples are analyzed for gene expression profile and microrna profile.

Eligibility criteria:
inclusion criteria: * samples of rtk and atrt provided by the children?s oncology group (cog)
proximal effects of alcohol on same-sex intimate partner violence

Conditions: Alcohol Consumption; Violence, Domestic; Stress, Psychological; Aggression

Summary: we will recruit sexual and gender minority couples to complete 56 days of daily surveys in order to evaluate (1) the impact of covid-19 stress and sexual and gender minority stress on heavy episodic drinking and intimate partner violence (ipv) perpetration, and (2) a brief, mobile-phone delivered text messaging intervention to mitigate the effects of these stressors. this project has high potential to inform how pandemic stress contributes to etiological models of alcohol-related ipv perpetration in sexual and gender minority couples and inform a culturally-sensitive, low burden, and easy to disseminate intervention to mitigate these effects critical during a pandemic when access to care is limited.


Eligibility criteria:
inclusion criteria (applies to both partners): * both partners must identify as cisgender and sexual minority or at least one partner must identify as a gender minority (i.e., one's gender identity is non-congruent with their sex assigned at birth) * 21 years or older * in an intimate relationship lasting at least one month in which there are at least 2 days of face-to-face contact each week * consumption of 4 (assigned female at birth) or 5 (assigned male at birth) alcoholic drinks on at least three days in the past year exclusion criteria: * seeking treatment or being in recovery for an alcohol or substance use disorder. * endorsement of severe physical ipv (e.g., use of a weapon) in the past year. * women who self-report that they are trying to get pregnant, that they are currently pregnant, or that they are currently breastfeeding .

Keywords: sexual minority gender minority
the relationship between intake of macro and micronutrients with clinical outcomes of head and neck cancer patients

Conditions: Head and Neck Cancer

Summary: cancer is a disease caused by uncontrolled cells growth, and its incidence is increasing worldwide. one of the most common cancer is head and neck cancer (hnc), which has low survival rate. malnutrition occurrence in hnc lower immune system and as result, decreased survival rate was found. risk factors including tumor histopathology, nutritional status, immune system, and environment have various effects on life expectancy. head and neck cancer treatments such as radiotherapy, chemotherapy, and surgery are not without complications. xerostomia, stomatitis, anorexia, nausea and vomiting, dysgeusia, ageusia, also pain are commonly found during the hnc treatment procedure, and takes part in further undernutrition findings in hnc patients. adequate nutrition management has favorable impact in managing hnc patients' malnutrition related problems. not only energy intake, but also macronutrients and micronutrients intake have been proved be beneficial in the outcomes of hnc patients. branched-chain amino acids (bcaa) and zinc are namely two nutrients that have been hypothesized to be beneficent. branched-chain amino acids are found to increase muscle mass, amino acid pools, and immune system, which resulted in preventing malnutrition and cachexia, also increasing total lymphocyte count in cancer patients. zinc plays role in immune system, antioxidant process, and taste bud functions. zinc supplementation is correlated to give a better outcome in taste perception and stomatitis in hnc patients who undergo radiotherapy. this study aims to finds the correlation between bcaa intake with muscle mass and lymphocyte count in hnc patients who haven't undergone chemoradiotherapy, zinc correlation with gustatory in hnc patients who haven't undergone chemoradiotherapy, zinc correlation with stomatitis in hnc patients who is having radiotherapy treatment, and energy and protein intake with body weight in hnc patients after underwent radiotherapy.


Eligibility criteria:
inclusion criteria: * head and neck cancer patients who haven't undergone radiotherapy or chemotherapy, during radiotherapy, and after radiotherapy exclusion criteria: * have contraindications for body composition measuring * are immunodeficient or have autoimmune disease * during immunosuppressant drugs treatment